Twist Bioscience (NASDAQ:TWST) Shares Gap Down to $49.28

Twist Bioscience Co. (NASDAQ:TWST)’s share price gapped down prior to trading on Monday . The stock had previously closed at $49.28, but opened at $48.29. Twist Bioscience shares last traded at $50.59, with a volume of 79,665 shares.

Analyst Ratings Changes

A number of research analysts have recently issued reports on TWST shares. Robert W. Baird lifted their price objective on shares of Twist Bioscience from $39.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Guggenheim started coverage on Twist Bioscience in a report on Tuesday, June 4th. They set a “buy” rating and a $53.00 price objective for the company. Scotiabank upped their target price on Twist Bioscience from $43.00 to $48.00 and gave the company a “sector outperform” rating in a research report on Monday, May 6th. TD Cowen raised their price target on Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, June 13th. Finally, Barclays increased their price objective on shares of Twist Bioscience from $45.00 to $60.00 and gave the company an “overweight” rating in a research report on Friday. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $48.50.

Twist Bioscience Price Performance

The firm’s fifty day simple moving average is $43.84 and its 200 day simple moving average is $38.39. The company has a market capitalization of $2.94 billion, a PE ratio of -14.67 and a beta of 1.78.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Thursday, May 2nd. The company reported ($0.79) EPS for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.05. The firm had revenue of $75.30 million for the quarter, compared to the consensus estimate of $70.70 million. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. The company’s revenue was up 25.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.06) earnings per share. On average, equities research analysts anticipate that Twist Bioscience Co. will post -3.08 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Emily M. Leproust sold 1,132 shares of Twist Bioscience stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $32.74, for a total value of $37,061.68. Following the completion of the transaction, the chief executive officer now owns 514,149 shares in the company, valued at approximately $16,833,238.26. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Twist Bioscience news, CEO Emily M. Leproust sold 1,132 shares of the stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $32.74, for a total transaction of $37,061.68. Following the transaction, the chief executive officer now directly owns 514,149 shares of the company’s stock, valued at $16,833,238.26. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Emily M. Leproust sold 4,163 shares of the business’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $37.13, for a total transaction of $154,572.19. Following the sale, the chief executive officer now directly owns 509,986 shares of the company’s stock, valued at approximately $18,935,780.18. The disclosure for this sale can be found here. Over the last quarter, insiders sold 19,426 shares of company stock worth $777,966. Company insiders own 3.92% of the company’s stock.

Institutional Trading of Twist Bioscience

Several large investors have recently made changes to their positions in the company. American International Group Inc. grew its holdings in shares of Twist Bioscience by 0.8% during the first quarter. American International Group Inc. now owns 28,506 shares of the company’s stock worth $978,000 after buying an additional 213 shares in the last quarter. D.A. Davidson & CO. grew its stake in Twist Bioscience by 3.4% during the 4th quarter. D.A. Davidson & CO. now owns 16,774 shares of the company’s stock valued at $618,000 after acquiring an additional 554 shares in the last quarter. EdgeRock Capital LLC acquired a new stake in Twist Bioscience in the 4th quarter valued at about $30,000. Swiss National Bank lifted its stake in Twist Bioscience by 0.8% in the 1st quarter. Swiss National Bank now owns 114,000 shares of the company’s stock worth $3,911,000 after purchasing an additional 900 shares in the last quarter. Finally, ProShare Advisors LLC boosted its holdings in shares of Twist Bioscience by 10.2% during the 1st quarter. ProShare Advisors LLC now owns 14,444 shares of the company’s stock worth $496,000 after purchasing an additional 1,336 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.